The rapid plasma reagin test market is likely to register a CAGR of 4% during the forecast period, and is anticipated to reach a market share of US$ 68.51 Mn in 2032, from US$ 46.28 Mn in 2022, owing to the growing demand for the rapid testing to reduce time consumption and need of instruments.
| Attributes | Details |
| Rapid Plasma Reagin Test Market CAGR | 4% |
| Rapid Plasma Reagin Test Market Size (2022) | US$ 46.28 Mn |
| Rapid Plasma Reagin Test Market Size (2032) | US$ 68.51 Mn |
One of the most common sexually transmitted infections is syphilis. According to the World Health Organisation, around 5.6 million new cases of syphilis were reported worldwide in 2012 among adults and adolescents aged 15 to 49. This is one of the major factors for higher sales of rapid plasma reagin test.
The demand for rapid plasma reagin tests for early detection is increasing as a result of growing and non-profit organizations' initiatives to alleviate the burden of sexually transmitted illnesses. Syphilis can be cured if caught early enough; this emphasizes the need for accurate and prompt diagnosis, which results in urgent demand for rapid plasma reagin test.
The rapid plasma reagin test market is being driven by an increase in the prevalence of syphilis, increased awareness of sexually transmitted diseases, technical advancements. Introduction of new products enhancing the sales of rapid plasma reagin test kits.
The most common factor driving demand for rapid plasma reagin test solutions is the rising frequency of syphilis. The rapid plasma reagin test market is expected to develop due to rising demand for screening pregnant women for syphilis prevention in their children.
The sales of rapid plasma reagin test is growing due to rising demand for rapid testing to save time and reduce the requirement for instruments. The rapid plasma reagin test market is predicted to increase as a result of technological advancements and the introduction of new products.
The sales of rapid plasma reagin test is predicted to rise due to an increase in the number of healthcare testing programs and awareness campaigns for sexually transmitted diseases.
Low reimbursement rates for rapid plasma reagin test procedures are projected to limit the demand for rapid plasma reagin tests. In addition, limited awareness of sexually transmitted infections in the population of low and middle-income countries is projected to stymie the sales of rapid plasma reagin test kits.
Due to the increased use of new technologies and rapid test kits for syphilis testing, North America is likely to lead the rapid plasma reagin test market. As laboratory-based rapid testing demand for sexually transmitted infection grows, Europe is predicted to generate the second-highest rapid plasma reagin test market revenue share in the rapid plasma reagin test.
The Asia Pacific rapid plasma reagin test market share is predicted to grow at a faster rate due to increased sexually transmitted infection (STI) awareness efforts and the rising prevalence of STI illnesses.
As a result of increased awareness of sexually transmitted infections (STIs) and government programs for diagnostic testing, Asian countries such as India and China are predicted to develop at the fastest rate, with the higher sales of rapid plasma reagin test over the forecast period.
Some market participants in the global rapid plasma reagin test market across the value chain are Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), Abbott Laboratories, Siemens AG, Sekisui Diagnostics, Immunostics Inc., Cardinal Health, Inc., Sclavo Diagnostics International, Novacyt Group, Meridian Bioscience Inc., Arlington Scientific, Inc., Bio-Rad Laboratories, Inc. and other companies. With novel product formulations and launches, these prominent industry players are expected to boost rapid plasma reagin test market share growth.
| Report Attribute | Details |
| Growth rate | CAGR of 4% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 - 2020 |
| Forecast period | 2022 - 2032 |
| Quantitative units | Revenue in USD million, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
| Segments covered | Product type, design type, end use, region |
| Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
| Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
| Key companies profiled | Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Beckman Coulter Inc (Danaher Corporation), Abbott Laboratories, Siemens AG, Sekisui Diagnostics, Immunostics Inc., Cardinal Health, Inc., Sclavo Diagnostics International, Novacyt Group, Meridian Bioscience Inc., Arlington Scientific, Inc., Bio-Rad Laboratories, Inc. and other companies |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
The rapid plasma reagin test market is anticipated to register a CAGR of 4% during the forecast period.
The rapid plasma reagin test market share is anticipated to reach US$ 68.51 Mn in 2032.
Demand for the rapid plasma reagin test market is likely to rise, growing demand for the rapid testing to reduce time consumption and need of instruments.
Explore Similar Insights
Rapid Plasma Reagin Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
